Prescribing information

 

ADAKVEO® (crizanlizumab) is indicated for the prevention of recurrent VOCs in patients with SCD who are aged 16 years and over. It can be given as an add-on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate.1

ADAKVEO® has a conditional marketing authorisation and further evidence is awaited.

 

   

Rate this content: 
No votes yet
UK | March 2022 | 114773

Crizanlizumab▼ – clinical data training module feedback

 
1 Start 2 Section 2 3 Section 3 4 Section 4 5 Complete

Evaluation & Feedback Form

Having completed the module, we would be grateful if you would provide us with some feedback and answer the following 10 multiple choice questions. Please mark a point on the scale.

 

Reference

  1. ADAKVEO® (crizanlizumab) Summary of Product Characteristics.

UK | March 2022 | 114773

×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]